Brokers Offer Predictions for PepGen Inc.’s Q2 2024 Earnings (NASDAQ:PEPG)
PepGen Inc. (NASDAQ:PEPG – Free Report) – Research analysts at Leerink Partnrs lowered their Q2 2024 earnings per share estimates for PepGen in a research note issued to investors on Tuesday, May 14th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.71) for the quarter, down from their previous estimate of ($0.67). The consensus estimate for PepGen’s current full-year earnings is ($2.89) per share. Leerink Partnrs also issued estimates for PepGen’s Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at ($0.75) EPS, FY2024 earnings at ($2.82) EPS and FY2025 earnings at ($2.71) EPS.
PepGen (NASDAQ:PEPG – Get Free Report) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.19.
Other equities research analysts also recently issued research reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of PepGen in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of PepGen in a research report on Wednesday.
View Our Latest Research Report on PEPG
PepGen Stock Down 3.6 %
Shares of NASDAQ:PEPG opened at $13.16 on Friday. The company has a market cap of $426.61 million, a P/E ratio of -4.05 and a beta of 1.64. PepGen has a 52 week low of $3.72 and a 52 week high of $17.51. The business has a fifty day simple moving average of $13.16 and a 200-day simple moving average of $10.10.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PEPG. Acadian Asset Management LLC acquired a new position in PepGen in the first quarter valued at $30,000. Allspring Global Investments Holdings LLC acquired a new position in PepGen in the third quarter valued at $33,000. Rathbones Group PLC acquired a new position in PepGen in the third quarter valued at $315,000. Artal Group S.A. acquired a new position in PepGen in the first quarter valued at $2,940,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of PepGen by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock worth $3,454,000 after purchasing an additional 105,000 shares in the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.
Insider Activity
In related news, SVP Niels Svenstrup sold 10,000 shares of PepGen stock in a transaction on Friday, May 17th. The stock was sold at an average price of $13.41, for a total value of $134,100.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.97% of the company’s stock.
PepGen Company Profile
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Stories
Receive News & Ratings for PepGen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PepGen and related companies with MarketBeat.com’s FREE daily email newsletter.
